Although transcription factors of the basic helix-loop-helix family have been shown to regulate enhancers of lymphomagenic gammaretroviruses through E-box motifs, the overlap of an E-box motif (Egre) with the glucocorticoid response element (GRE) has obscured their function in vivo. We report here that Egre, but not the GRE, affects disease induction by the murine T-lymphomagenic SL3-3 virus. Mutating all three copies of Egre prolonged the tumor latency period from 60 to 109 days. Further mutating an E-box motif (Ea/s) outside the enhancer prolonged the latency period to 180 days, suggesting that Ea/s works as a backup site for Egre. While wild-type SL3-3 and GRE and Ea/s mutants exclusively induced T-cell lymphomas with wild-type latencies mainly of the CD4 ؉ CD8 ؊ phenotype, Egre as well as the Egre and Ea/s mutants induced B-cell lymphomas and myeloid leukemia in addition to T-cell lymphomas. T-cell lymphomas induced by the two Egre mutants had the same phenotype as those induced by wild-type SL3-3, indicating the incomplete disruption of T-cell lymphomagenesis, which is in contrast to previous findings for a Runx site mutant of SL3-3. Mutating the Egre site or Egre and Ea/s triggered several tumor phenotype-associated secondary enhancer changes encompassing neighboring sites, none of which led to the regeneration of an E-box motif. Taken together, our results demonstrate a role for the E-box but not the GRE in T lymphomagenesis by SL3-3, unveil an inherent broader disease specificity of the virus, and strengthen the notion of selection for more potent enhancer variants of mutated viruses during tumor development.Murine leukemia viruses (MLVs) are gammaretroviruses with strain-specific patterns of disease induction. The U3 transcriptional enhancers in the long terminal repeat (LTR) of MLVs share a common framework of binding sites for host transcription factors that contribute to the regulation of disease specificity (10,12,13,15,20,40,42,44,48,51). SL3-3 is a potent ecotropic MLV that induces strictly T-cell lymphomas in laboratory mice, with a mean latency of 2 to 4 months depending on the mouse strain (20,30,41,51). The SL3-3 enhancer consists of 2.5 tandem copies of a 72-bp sequence with binding sites for Runx, NF-1, c-Myb, and Ets factors as well as the glucocorticoid receptor (GR) and basic helix-loophelix (bHLH) factors. Runx and c-Myb binding sites are critical for tumor induction by 30,51,60), whereas Ets and NF-1 sites are less important (19,21,22,51,52,59,60). Besides significantly weakening the virus, the mutations of all Runx sites in the SL3-3 transcriptional enhancer (the SL3-3dm mutant) were found to shift disease patterns from exclusively T-cell lymphomas to various hematopoietic malignancies, including B-cell lymphomas and myeloid and erythroid leukemias (57).The roles of the glucocorticoid response element (GRE) and bHLH binding E-box motifs in tumor induction by SL3-3 have not been investigated; however, the binding of GR and bHLH factors affects SL3-3 transcriptional activity (10,11,29,49...